News in Brief

Suven passes US FDA inspection, secures CNS product patents

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/filmfoto)
(Image: Getty/filmfoto)
Suven Life Sciences has completed a US FDA renewal inspection at its Pashamylaram-based facility, which manufactures and supplies APIs, intermediates, and formulations.

Following a successful inspection and subsequent review, the facility was found compliant with regards to current good manufacturing processes (cGMP).

The US Food and Drug Administration (FDA) has determined inspection classification of this facility as “no action indicated (NAI), according to the contract development and manufacturing organization (CDMO).

To date, the facility has filed 19 drug master files (DMF) and five abbreviated new drug applications (ANDA).

Suven's drug discovery program is focused on discovering, developing and commercializing CNS therapies through the use of G-protein-coupled receptors (GPCR) targets.

The company currently has four clinical-stage compounds and nine internally-discovered therapeutic drug candidates in various stages of preclinical development.

In related news, Suven today announced that is has secured product patents in Australia, Eurasia, and Europe.

The patent covers its class of selective 5-HT4 compounds being developed for the treatment of cognitive impairment associated with neurodegenerative disorders.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,"​ said Venkat Jasti, Suven CEO, in a statement.

Related news

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more